Nabid A, Garant MP, Martin AG, et al. Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial. J Clin Oncol 35, 2017 (suppl; abstr 5008).
Neoadjuvant dostarlimab bij mismatch repair-deficiënte tumoren
jul 2025 | Gynaecologische oncologie, Immuuntherapie, Maag-darm-leveroncologie, Uro-oncologie